Lenalid

Lenalid is a generic drug that contains exactly the same active ingredients as Revlimid (Revlid).
The drug is used to treat multiple myeloma (a cancer that attacks plasma cells in the bone marrow).
 
Multiple myeloma is the second most common form of cancer in the blood cancer. Lenalid is an advanced (second generation drug) drug called thalidomide, which has also been used to treat multiple myeloma.
 
The drug belongs to a broader group of drugs that act on the immune system (immunomodulatory drugs). In addition, the drug has been shown to inhibit the formation of new blood vessels and thus inhibit the spread of cancer cells. In addition to myeloma therapy, the drug is used to treat a range of other health conditions (called myelodysplastic syndrome), in which the bone marrow does not produce enough healthy blood cells and in certain conditions of anemia.
 
The effect of the drug on the immune system may reduce the number of white cells produced in the bone marrow, thereby weakening the immune system and increasing the body's susceptibility to infections.
However, the course of treatment with Lenalid includes blood count tests. Treatment may also lead to the creation of congenital genetic defects and therefore avoid getting pregnant (a prohibition that applies to men and women alike) during treatment.
 
Lenalid is produced by Natco Pharma, one of the most recognized pharmaceutical companies in the world. The company, established in 1981, specializes in the research and development of drugs that provide therapeutic solutions to various medical problems.
The company has five manufacturing facilities in India as well as modern and innovative research laboratories, and has approved FDA drugs. It is one of the leading competitors in Teva, which markets drugs throughout the developed world, including the European Union, and has a branch in Canada.